Reports Q4 revenue $9.73M, consensus $8.67M. Anticipates that cash, cash equivalents and investment securities as of December 31, 2023 will be sufficient to fund planned operations for at least the next twelve months. “It was an exciting year for Fennec given the strong performance with PEDMARK in the first full fiscal year following its U.S. commercial launch. We are pleased with our execution against strategic plans and our momentum in 2023, which sets the stage for further success in 2024 and beyond. We also received European Commission and U.K. approvals of PEDMARQSI, which led to the recent announcement of an exclusive licensing agreement with Norgine for Europe, Australia and New Zealand,” said Rosty Raykov, CEO. “We have significantly strengthened our balance sheet through the agreement with Norgine, and we remain dedicated to further growing our revenues as we expand the availability of PEDMARK to patients and providers globally.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FENC:
- Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
- Fennec price target raised to $18 from $17 at Craig-Hallum
- Fennec Pharmaceuticals Strikes Major European Deal
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
- Fennec sees FY23 revenue $20.7M-$21.2M, consensus $19.57M
